Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VLA15 Lyme borreliosis vaccine in healthy pediatric and adult participants
2025-000381-28Phase 2
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Lyme Disease Vaccine Recombinant OspA in Lyme borreliosis (2 arms), sponsored by Pfizer. Primary endpoints: Safety endpoints and Immunogenicity endpoints.
02
Drugs
Lyme Disease Vaccine Recombinant OspA
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on 2025-000381-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000381-28.